Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents
Alzheimer's Disease (AD) is a neurodegenerative brain disorder in which many biological dysfunctions are involved. Among them, two main types of lesions were discovered and widely studied: the amyloid plaques and the neurofibrillary tangles (NFTs). These two lesions are caused by the dysfunctio...
Gespeichert in:
| Veröffentlicht in: | European journal of medicinal chemistry 2017-10, Vol.139, p.153-167 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 167 |
|---|---|
| container_issue | |
| container_start_page | 153 |
| container_title | European journal of medicinal chemistry |
| container_volume | 139 |
| creator | Jouanne, Marie Rault, Sylvain Voisin-Chiret, Anne-Sophie |
| description | Alzheimer's Disease (AD) is a neurodegenerative brain disorder in which many biological dysfunctions are involved. Among them, two main types of lesions were discovered and widely studied: the amyloid plaques and the neurofibrillary tangles (NFTs). These two lesions are caused by the dysfunction and the accumulation of two proteins which are, respectively, the beta-amyloid peptide and the tau protein. The process that leads these two proteins to aggregate is complex and is the subject of current studies. After a brief description of the aggregation mechanisms, we will provide an overview of new therapeutic agents targeting the different dysfunctions and toxic species found during aggregation.
[Display omitted]
•Tau protein and its aggregation in Alzheimer's disease.•Dysfunctions and toxic species found during aggregation.•Preliminary update of the known biophysical events leading to tauopathies.•Promising therapies targeting events related to aggregation. |
| doi_str_mv | 10.1016/j.ejmech.2017.07.070 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02043725v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523417305925</els_id><sourcerecordid>28800454</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-477959ca027778c588feaba97c57d4867d102339c8f25d501221f6727ca65e253</originalsourceid><addsrcrecordid>eNp9kFFr2zAQx0VZabK236AUvY0-ODvJkuXsYRBKtw4CfWmfhSqfE4XYMpJi2D79ZNzlcXBw3N3vf8f9CbljsGLAqq-HFR46tPsVB6ZWMAVckCVTVV2UXIpPZAmcl4XkpViQzzEeAEBWAFdkwesaQEixJOnVnOgQfELXU7PbBdyZ5HxPc7k5_tmj6zB8ibRxEU3Eb3STsZSCscmNSJMJO0y09YGmPdIGRzz6ocM-Ud_S3udyGgQz4Ck5my_kUbwhl605Rrz9yNfk7cfT6-NzsX35-etxsy2sqHgqhFJrubYGuFKqtrKuWzTvZq2sVI2oK9Uw4GW5tnXLZSOBcc7aSnFlTSWRy_KaPMx79-aoh-A6E35rb5x-3mz11AMOolRcjiyzYmZt8DEGbM8CBnoyXB_0bLieDNcwBWTZ_SwbTu8dNmfRP4cz8H0GMD86Ogw6Woe9xcYFtEk33v3_wl-aLZNg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Jouanne, Marie ; Rault, Sylvain ; Voisin-Chiret, Anne-Sophie</creator><creatorcontrib>Jouanne, Marie ; Rault, Sylvain ; Voisin-Chiret, Anne-Sophie</creatorcontrib><description>Alzheimer's Disease (AD) is a neurodegenerative brain disorder in which many biological dysfunctions are involved. Among them, two main types of lesions were discovered and widely studied: the amyloid plaques and the neurofibrillary tangles (NFTs). These two lesions are caused by the dysfunction and the accumulation of two proteins which are, respectively, the beta-amyloid peptide and the tau protein. The process that leads these two proteins to aggregate is complex and is the subject of current studies. After a brief description of the aggregation mechanisms, we will provide an overview of new therapeutic agents targeting the different dysfunctions and toxic species found during aggregation.
[Display omitted]
•Tau protein and its aggregation in Alzheimer's disease.•Dysfunctions and toxic species found during aggregation.•Preliminary update of the known biophysical events leading to tauopathies.•Promising therapies targeting events related to aggregation.</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2017.07.070</identifier><identifier>PMID: 28800454</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Aggregation ; Alzheimer Disease - drug therapy ; Alzheimer Disease - metabolism ; Alzheimer's disease ; Animals ; Chemical Sciences ; Humans ; Medicinal Chemistry ; Neuroprotective Agents - chemistry ; Neuroprotective Agents - pharmacology ; Protein Aggregates - drug effects ; Tau protein ; tau Proteins - antagonists & inhibitors ; tau Proteins - metabolism ; Therapeutic agents</subject><ispartof>European journal of medicinal chemistry, 2017-10, Vol.139, p.153-167</ispartof><rights>2017 Elsevier Masson SAS</rights><rights>Copyright © 2017 Elsevier Masson SAS. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-477959ca027778c588feaba97c57d4867d102339c8f25d501221f6727ca65e253</citedby><cites>FETCH-LOGICAL-c462t-477959ca027778c588feaba97c57d4867d102339c8f25d501221f6727ca65e253</cites><orcidid>0000-0001-5564-2244</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0223523417305925$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28800454$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-02043725$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Jouanne, Marie</creatorcontrib><creatorcontrib>Rault, Sylvain</creatorcontrib><creatorcontrib>Voisin-Chiret, Anne-Sophie</creatorcontrib><title>Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>Alzheimer's Disease (AD) is a neurodegenerative brain disorder in which many biological dysfunctions are involved. Among them, two main types of lesions were discovered and widely studied: the amyloid plaques and the neurofibrillary tangles (NFTs). These two lesions are caused by the dysfunction and the accumulation of two proteins which are, respectively, the beta-amyloid peptide and the tau protein. The process that leads these two proteins to aggregate is complex and is the subject of current studies. After a brief description of the aggregation mechanisms, we will provide an overview of new therapeutic agents targeting the different dysfunctions and toxic species found during aggregation.
[Display omitted]
•Tau protein and its aggregation in Alzheimer's disease.•Dysfunctions and toxic species found during aggregation.•Preliminary update of the known biophysical events leading to tauopathies.•Promising therapies targeting events related to aggregation.</description><subject>Aggregation</subject><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer's disease</subject><subject>Animals</subject><subject>Chemical Sciences</subject><subject>Humans</subject><subject>Medicinal Chemistry</subject><subject>Neuroprotective Agents - chemistry</subject><subject>Neuroprotective Agents - pharmacology</subject><subject>Protein Aggregates - drug effects</subject><subject>Tau protein</subject><subject>tau Proteins - antagonists & inhibitors</subject><subject>tau Proteins - metabolism</subject><subject>Therapeutic agents</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kFFr2zAQx0VZabK236AUvY0-ODvJkuXsYRBKtw4CfWmfhSqfE4XYMpJi2D79ZNzlcXBw3N3vf8f9CbljsGLAqq-HFR46tPsVB6ZWMAVckCVTVV2UXIpPZAmcl4XkpViQzzEeAEBWAFdkwesaQEixJOnVnOgQfELXU7PbBdyZ5HxPc7k5_tmj6zB8ibRxEU3Eb3STsZSCscmNSJMJO0y09YGmPdIGRzz6ocM-Ud_S3udyGgQz4Ck5my_kUbwhl605Rrz9yNfk7cfT6-NzsX35-etxsy2sqHgqhFJrubYGuFKqtrKuWzTvZq2sVI2oK9Uw4GW5tnXLZSOBcc7aSnFlTSWRy_KaPMx79-aoh-A6E35rb5x-3mz11AMOolRcjiyzYmZt8DEGbM8CBnoyXB_0bLieDNcwBWTZ_SwbTu8dNmfRP4cz8H0GMD86Ogw6Woe9xcYFtEk33v3_wl-aLZNg</recordid><startdate>20171020</startdate><enddate>20171020</enddate><creator>Jouanne, Marie</creator><creator>Rault, Sylvain</creator><creator>Voisin-Chiret, Anne-Sophie</creator><general>Elsevier Masson SAS</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0001-5564-2244</orcidid></search><sort><creationdate>20171020</creationdate><title>Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents</title><author>Jouanne, Marie ; Rault, Sylvain ; Voisin-Chiret, Anne-Sophie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-477959ca027778c588feaba97c57d4867d102339c8f25d501221f6727ca65e253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aggregation</topic><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer's disease</topic><topic>Animals</topic><topic>Chemical Sciences</topic><topic>Humans</topic><topic>Medicinal Chemistry</topic><topic>Neuroprotective Agents - chemistry</topic><topic>Neuroprotective Agents - pharmacology</topic><topic>Protein Aggregates - drug effects</topic><topic>Tau protein</topic><topic>tau Proteins - antagonists & inhibitors</topic><topic>tau Proteins - metabolism</topic><topic>Therapeutic agents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jouanne, Marie</creatorcontrib><creatorcontrib>Rault, Sylvain</creatorcontrib><creatorcontrib>Voisin-Chiret, Anne-Sophie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jouanne, Marie</au><au>Rault, Sylvain</au><au>Voisin-Chiret, Anne-Sophie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2017-10-20</date><risdate>2017</risdate><volume>139</volume><spage>153</spage><epage>167</epage><pages>153-167</pages><issn>0223-5234</issn><eissn>1768-3254</eissn><abstract>Alzheimer's Disease (AD) is a neurodegenerative brain disorder in which many biological dysfunctions are involved. Among them, two main types of lesions were discovered and widely studied: the amyloid plaques and the neurofibrillary tangles (NFTs). These two lesions are caused by the dysfunction and the accumulation of two proteins which are, respectively, the beta-amyloid peptide and the tau protein. The process that leads these two proteins to aggregate is complex and is the subject of current studies. After a brief description of the aggregation mechanisms, we will provide an overview of new therapeutic agents targeting the different dysfunctions and toxic species found during aggregation.
[Display omitted]
•Tau protein and its aggregation in Alzheimer's disease.•Dysfunctions and toxic species found during aggregation.•Preliminary update of the known biophysical events leading to tauopathies.•Promising therapies targeting events related to aggregation.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>28800454</pmid><doi>10.1016/j.ejmech.2017.07.070</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0001-5564-2244</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0223-5234 |
| ispartof | European journal of medicinal chemistry, 2017-10, Vol.139, p.153-167 |
| issn | 0223-5234 1768-3254 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_02043725v1 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aggregation Alzheimer Disease - drug therapy Alzheimer Disease - metabolism Alzheimer's disease Animals Chemical Sciences Humans Medicinal Chemistry Neuroprotective Agents - chemistry Neuroprotective Agents - pharmacology Protein Aggregates - drug effects Tau protein tau Proteins - antagonists & inhibitors tau Proteins - metabolism Therapeutic agents |
| title | Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T00%3A24%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tau%20protein%20aggregation%20in%20Alzheimer's%20disease:%20An%20attractive%20target%20for%20the%20development%20of%20novel%20therapeutic%20agents&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Jouanne,%20Marie&rft.date=2017-10-20&rft.volume=139&rft.spage=153&rft.epage=167&rft.pages=153-167&rft.issn=0223-5234&rft.eissn=1768-3254&rft_id=info:doi/10.1016/j.ejmech.2017.07.070&rft_dat=%3Cpubmed_hal_p%3E28800454%3C/pubmed_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/28800454&rft_els_id=S0223523417305925&rfr_iscdi=true |